July 29, 2020 -- Vaccine development firm Intravacc and biopharmaceutical contract development and manufacturing organization Celonic are teaming up to develop a COVID-19 vaccine.
The vaccine will combine an immunogenic spike protein of SARS-CoV-2 expressed by Celonic's Chovolution mammalian cell expression system with Intravacc's Outer Membrane Vesicle (OMV) technology, according to the companies. The firms aim to generate a balanced B- and T-cell response against SARS-CoV-2 with the vaccine.
Celonic said it will construct cell lines producing the spike protein in large quantities and develop a good manufacturing practice production process. The companies expect to begin preclinical studies shortly in order to select the best candidate protein for the vaccine. In addition, the collaboration aims to accelerate the development of Intravacc's COVID-19 OMV protein vaccine, which is expected to enter clinical testing in 2021.